Abbott Laboratories (ABT) Financials
Key financial figures for Abbott Laboratories (Q3 2026).
Abbott Q3 2026 net sales rose 14.5% reported and 7.0% comparable to $13,013M with adjusted EPS of $1.42, while full-year comparable sales growth guidance moved to about 6.0% from 6.5-7.5%. Net sales were $13,013M, up 14.5% reported and 7.0% comparable (Exact Sciences, acquired March 23, 2026, is included in both periods for the comparable measure). Adjusted diluted EPS was $1.42 versus $1.30 a year earlier, at the midpoint of the $1.38 to $1.46 range given in July; GAAP diluted EPS was $0.53 versus $0.94. Specified items cost $0.89 per share, including intangible amortization of $841M and approximately $670M of legal charges to resolve the Gill case and NEC claims for approximately 2,000 additional infants. On the outlook: Full-year 2026 adjusted diluted EPS of $5.50 to $5.55 (midpoint of the prior $5.45 to $5.60 range reaffirmed); fourth-quarter 2026 adjusted diluted EPS of $1.62 to $1.67; full-year 2026 comparable sales growth of approximately 6.0% (previously 6.5% to 7.5%). Figures are for Q3 2026, as Abbott Laboratories reported them.
- Revenue
- $13.0B
- Net Income
- $920M
- EPS
- $0.53
- Total Assets
- $108.2B
- Operating Cash Flow
- $1.7B
Recent quarters
| Period | Revenue | Net Income | EPS | Operating Margin | Free Cash Flow |
|---|---|---|---|---|---|
| Q3 FY2026 | $13.0B | $920M | $0.53 | 11.34% | $1.2B |
| Q2 FY2026 | $12.6B | $928M | $0.53 | 14.15% | |
| Q1 FY2026 | $11.2B | $1.1B | $0.61 | 12.05% | $916M |
| Q4 FY2025 | $11.5B | $1.8B | $1.02 | 19.64% | $2.6B |
| Q3 FY2025 | $11.4B | $1.6B | $0.94 | 18.09% | $2.3B |
Recent fiscal years
| Period | Revenue | Net Income | EPS | Operating Margin | Free Cash Flow |
|---|---|---|---|---|---|
| FY2025 | $44.3B | $6.5B | $3.72 | 18.16% | $7.4B |
| FY2024 | $42.0B | $13.4B | $7.64 | 16.27% | $6.4B |
| FY2023 | $40.1B | $5.7B | $3.26 | 16.04% | $5.1B |
Frequently asked questions
What was Abbott Laboratories's revenue last quarter?
Abbott Laboratories reported revenue of $13.01 billion for Q3 FY2026, up 14.5% from the same period a year earlier.
Is Abbott Laboratories profitable?
Yes. Abbott Laboratories reported net income of $920.0 million for Q3 FY2026, a net margin of 7.07% on revenue.
How has Abbott Laboratories's margin trended?
Operating margin was 11.34% in Q3 FY2026, compared with 18.09% in the same period a year earlier. The quarter by quarter series is on the SentiSense financials page.
How much free cash flow did Abbott Laboratories generate?
Abbott Laboratories generated free cash flow of $1.22 billion in Q3 FY2026, after capital expenditure.
Full income statement, balance sheet and cash flow for Abbott Laboratories on SentiSense, with up to forty quarters and twenty fiscal years of history.